David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 22,575 shares at $29.71 ($653K) on 2026-05-11, disclosed to the SEC on 2026-05-13.
Scheduled sale ($653k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.71 | 2,171 | $65K | 9.9% |
| 2 | $29.36 | 6,348 | $186K | 28.6% |
| 3 | $28.58 | 14,056 | $402K | 61.6% |
| Total | $28.91 avg | 22,575 | $653K | 100% |
| Filing → |
| MLYS | SELL | 2026-07-15 | $557K | — | Filing → |
| MLYS | SELL | 2026-07-10 | $66K | — | Filing → |
| MLYS | SELL | 2026-06-17 | $350K | — | Filing → |